HIGHLIGHTS
- who: Niccolu00f2 Bitto and collaborators from the Thrombosis Center, Milan, Italy Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy have published the Article: Improving Management of Portal Hypertension: The Potential Benefit of Non-Etiological Therapies in Cirrhosis, in the Journal: (JOURNAL)
- what: The most robust clinical evidence on the disease-modifying role of anticoagulants on cirrhosis comes from a seminal non-blinded randomized trial, in which 70 cirrhotic patients were randomly assigned to receive enoxaparin (4000 IU/day for 48 weeks) or no treatment, with the primary objective of preventing PVT .
-
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.